Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation has taken a major decision that is expected to elevate its growth prospect further. The pharmaceutical giant is ready to buy sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal.

Both the companies have approved the deal and now they are waiting for regulatory approvals to close this deal. It is believed that this acquisition will boost work in rare hematology. Founded in 2011, Global Blood Therapeutics is known for its Oxbryta tablets that are used to cure sickle cell disease.

It is interesting to see here that Pfizer’s buying spree continues since the outbreak of the pandemic. The drug maker has announced deals close to $19 billion in the last one year alone. According to business experts, Pfizer is economically doing great and earning quite remarkably with the sale of COVID vaccines. All recent acquisitions are results of its successful vaccine adaptability in the market.

Pfizer aims to touch $25 billion in sales by 2030 from new business developments.

Aamir Malik, the company’s chief business innovation officer, told analysts recently that Pfizer was “leaving very few stones unturned” in looking for expansion opportunities. Malik said Pfizer was looking for deals that will add substantial value either scientifically or commercially.

“I think we’re very excited about the opportunities that are ahead of us and the flexibility that our balance sheet gives us to pursue those,” he said during a call to discuss second-quarter results.